Elicio Therapeutics, Inc.ELTXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-28.78%
↓ 232% below average
Average (23q)
21.83%
Historical baseline
Range
High:412.64%
Low:-77.21%
Volatility
2243.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -28.78% |
| Q2 2025 | -9.93% |
| Q1 2025 | -26.79% |
| Q4 2024 | 47.39% |
| Q3 2024 | -11.88% |
| Q2 2024 | 8.22% |
| Q1 2024 | 22.77% |
| Q4 2023 | -15.24% |
| Q3 2023 | 46.93% |
| Q2 2023 | -9.85% |
| Q1 2023 | 37.24% |
| Q4 2022 | -13.00% |
| Q3 2022 | -8.89% |
| Q2 2022 | -56.67% |
| Q1 2022 | 75.33% |
| Q4 2021 | -49.95% |
| Q3 2021 | -8.06% |
| Q2 2021 | 216.66% |
| Q1 2021 | -58.80% |
| Q4 2020 | 81.97% |
| Q3 2020 | -50.14% |
| Q2 2020 | 412.64% |
| Q1 2020 | -77.21% |
| Q4 2019 | 0.00% |